SVRA vs JANX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SVRA · Savara$4.83 ▲ 10.27%
JANX · Janux Therapeutics$17.63 ▲ 9.78%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SVRA +20.8%
- JANX -36.1%
Head to head
| Metric | SVRA | JANX |
|---|---|---|
| Price | $4.83 | $17.63 |
| Change today | ▲ 10.27% | ▲ 9.78% |
| Market cap | $992.37M | $1.08B |
| Return, 3 months | -15.7% | +7.4% |
| Return, year to date | -19.9% | +27.8% |
| Return, 1 year | +22.3% | -33.4% |
| P/E (TTM) | – | – |
| P/B | 6.9 | 1.2 |
| P/E percentile vs own 5y | 51st | 48th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -32.3% | +35.1% |
| Gross margin | – | – |
| Operating margin | – | -598.1% |
| Net margin | – | -427.5% |
| Return on equity | -105.5% | -10.7% |
| Analyst target vs. price | +131.9% | +89.4% |
| Analyst buy share | 100% | 91% |
| RSI (14) | 51 | 52 |
| 30-day volatility | 63.3% | 61.4% |
| Max drawdown, 1 year | -39.2% | -64.9% |
| Trend read | Leaning bullish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- JANX is the largest of the group by market value.
- SVRA has returned the most over the past year.
- JANX has been the calmest stock over the last 30 days.